# ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

> **NCT03145298** · PHASE1 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **BIOLOGICAL:** Allogeneic Human Cardiosphere-Derived Stem Cells
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03145298
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145298, "ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03145298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*